Missing generic hurts Rite Aid

Share this content:

Lower reimbursement rates are eating into Rite Aid's financial outlook. Bloomberg reports that this was just one reason the drugstore chain cited for dialing back its full-year forecast. Another: the FDA ban on four Ranbaxy plants means generic Nexium is a no-show, adding to the chain's financial pain.

Share this content:
Scroll down to see the next article